CellSeed Inc. (7776) AI Stock Analysis

• Market Cap: ¥15.77B
• Dividend Yield: N/A
• Average Volume (3M): 545.97K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.99
• Revenue Growth: -22.81%
• EPS Growth: 2.69%
• Country: JP
• Employees: 44
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -7.42
• Shares Outstanding: 34,666,420
• 10 Day Avg. Volume: 384,740
• 30 Day Avg. Volume: 545,973
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: ¥468.00
• Price Target Upside: 2.86% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 0

• Rating: 51 Neutral
• Price Target: ¥476.00 ▲(4.62% Upside)

CellSeed Inc.'s overall stock score is primarily impacted by its financial performance, which highlights significant challenges in profitability and cash flow. Technical analysis suggests neutral momentum, while valuation concerns due to negative earnings further weigh down the score. The absence of earnings call insights and corporate events means these factors do not influence the score.

CellSeed Inc. Business Overview & Revenue Model

Company Description

CellSeed Inc. develops cell sheet regenerative medicines. It is involved in the research, development, and commercialization of cell-sheet regenerative medicine products, such as epithelial cell sheet for esophageal regeneration, regenerated cartilage sheet, and chondrocyte sheet for the treatment of knee osteoarthritis. The company also offers UpCell, a temperature-responsive cell cultureware for cell-sheet engineering; RepCell, a temperature-responsive cell cutureware for cell collection; and HydroCell, a low cell binding cultureware. In addition, it provides peripheral equipment, including ThermoPlate III, a heating element made by a transparent glass plate; and cellZscope, an automated cell monitoring system, as well as contract development and manufacturing services. The company was incorporated in 2001 and is headquartered in Tokyo, Japan.

How the Company Makes Money

CellSeed Inc. generates revenue primarily through the development and licensing of its proprietary cell sheet engineering technology. The company partners with medical institutions and pharmaceutical companies to develop regenerative therapies, earning income from licensing fees, research and development collaborations, and milestone payments. Additionally, CellSeed Inc. may generate revenue from the sale of its regenerative medicine products once they receive regulatory approval and are commercialized.

CellSeed Inc. Financial Statement Overview

Summary

CellSeed Inc. faces significant financial challenges, particularly in profitability and operational cash flows. The balance sheet remains stable with strong equity, but ongoing net losses and negative cash flows highlight the need for strategic changes to improve financial health and sustainability.

Income Statement

CellSeed Inc. shows a consistent negative EBIT and net income over the years, indicating ongoing operational challenges. Gross profit margin has declined significantly from 2019 to 2024, reflecting increased cost pressures. Revenue growth has been volatile, with declines in recent years, suggesting struggles in maintaining sales momentum.

Balance Sheet

The company's balance sheet shows a strong equity position with a high equity ratio, indicating financial stability. However, the consistent net losses have impacted return on equity negatively. Debt levels remain low, reducing leverage risk, but stagnant equity growth poses challenges for future financing.

Cash Flow

CellSeed Inc.'s cash flow statement highlights negative operating and free cash flows, which are concerning for liquidity and operational sustainability. Despite significant financing activities, the reliance on external funding may not be sustainable long-term. The cash flow to net income ratio indicates challenges in converting earnings to cash.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	193.28M	190.13M	126.43M	161.67M	199.47M
Gross Profit	110.11M	107.16M	61.02M	84.04M	138.19M
EBITDA	-855.49M	-836.52M	-750.00M	-905.67M	-770.13M
Net Income	-859.84M	-846.53M	-759.68M	-912.87M	-783.86M
Balance Sheet
Total Assets	2.43B	2.47B	1.54B	1.41B	1.81B
Cash, Cash Equivalents and Short-Term Investments	2.13B	2.16B	1.07B	846.67M	1.46B
Total Debt	143.75M	151.25M	158.75M	160.00M	160.00M
Total Liabilities	269.88M	301.05M	365.58M	363.58M	280.08M
Stockholders Equity	2.16B	2.16B	1.18B	1.04B	1.53B
Cash Flow
Free Cash Flow	-884.47M	-801.07M	-733.60M	-908.15M	-710.96M
Operating Cash Flow	-866.10M	-779.43M	-718.01M	-817.15M	-700.68M
Investing Cash Flow	-18.37M	56.31M	61.73M	-110.44M	-12.62M
Financing Cash Flow	855.48M	1.81B	881.81M	396.88M	1.10B

CellSeed Inc. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 455.00
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:7776, the sentiment is Negative. The current price of 455 is below the 20-day moving average (MA) of 472.65, below the 50-day MA of 473.66, and below the 200-day MA of 467.04, indicating a bearish trend. The MACD of -0.86 indicates Positive momentum. The RSI at 40.65 is Neutral, neither overbought nor oversold. The STOCH value of 34.32 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:7776.

CellSeed Inc. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
7096	70 Outperform	¥9.63B	38.36	14.68%	―	4.58%	-39.30%
7774	58 Neutral	¥20.71B	-72.28	―	―	6.33%	-250.29%
7776	51 Neutral	¥15.77B	―	―	―	-22.81%	2.69%
4889	51 Neutral	¥22.93B	361.15	―	―	-27.00%	―
4978	49 Neutral	¥19.05B	-151.53	―	―	13.83%	34.66%
4599	47 Neutral	¥18.83B	-9.73	―	―	―	5.59%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%